Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial.

MLA

Udell, Jacob A., et al. “Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial.” Diabetes Care, vol. 38, no. 4, Apr. 2015, pp. 696–705. EBSCOhost, https://doi.org/10.2337/dc14-1850.

APA

Udell, J. A., Bhatt, D. L., Braunwald, E., Cavender, M. A., Mosenzon, O., Steg, P. G., Davidson, J. A., Nicolau, J. C., Corbalan, R., Hirshberg, B., Frederich, R., KyungAh Im, Umez-Eronini, A. A., He, P., McGuire, D. K., Leiter, L. A., Raz, I., & Scirica, B. M. (2015). Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial. Diabetes Care, 38(4), 696–705. https://doi.org/10.2337/dc14-1850

Chicago

Udell, Jacob A., Deepak L. Bhatt, Eugene Braunwald, Matthew A. Cavender, Ofri Mosenzon, Ph. Gabriel Steg, Jaime A. Davidson, et al. 2015. “Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial.” Diabetes Care 38 (4): 696–705. doi:10.2337/dc14-1850.